KEMA Quality, which tested the device, found that it met CE Mark standards.
Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT) portfolio company IOptima Ltd. has been notified by KEMA Quality BV that the company's laser-based device for treating glaucoma complies with EU CE Mark standards. KEMA will therefore recommend approving the device.
IOptima's OT-135 is a non-invasive treatment for glaucoma by thinning the sclera wall without penetrating it. When IOptima obtained CE Mark certification, it will be able to market the device in Europe.
Published by Globes [online], Israel business news - www.globes-online.com - on May 13, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
Gali Weinreb and Hanan Lifshitz